Skip to content

GeneDx Holdings

US · WGS #2702 by market cap Listed 1970
45.46 -3.78 -7.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 6.41 In line with history 62nd percentile
5-year average 4.98 · #27 of 41 in Diagnostics & Research
P/E ratio -13.93 Cheap vs history 29th percentile
5-year average 135.96 · forward -53.95
P/S ratio 3.41 In line with history 51st percentile
5-year average 3.83 · forward 2.92 · #20 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
GeneDx Holdings (WGS) 1.36B -12.09 5.57 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value64.61 Economic moatNone UncertaintyHigh

Trading 42.1% below Morningstar's fair value estimate.

Fair value

GeneDx Holdings Corp receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 19% discount to our quantitative fair value estimate of $64.61 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet increases our valuation estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of -25.6 ranks in the bottom 10% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's cash flow yield of -0.02%, for example, ranks in the bottom 30% compared with global peers. At the current valuation, the yield of cash flow from operations to investors looks paltry. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

GeneDx Holdings discussion 0 comments

Add a comment